January 21, 2026

National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051
Symbol: LUPIN

BSE Limited
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
Mumbai - 400 001

Scrip Code: Equity - 500257

Subject: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

We are pleased to enclose a Press Release titled "Lupin and Galenicum Sign License and Supply Agreement for Semaglutide in 23 Countries."

The same is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

AMIT KUMAR GUPTA

Digitally signed by AMIT KUMAR GUPTA
DN: c=IN, st=Maharashtra,
2.5.4.20=f72cf02f52d2a7e595b45b84659bdca28c8f26a939bb35835a169f2a237229a3, postalCode=400705,
street=C701 Shivdarshan CHS Ltd Sector16 Plot No5 Navi Mumbai,
pseudonym=d3a468d0d03546efabffd2a7cb7aaaae,
title=7825,
serialNumber=de9bbd80d8994e4be9f0dd23991144eba7e782d70287df6aad1994f0b52f2fa08a, o=Personal,
cn=AMIT KUMAR GUPTA
Date: 2026.01.21 07:35:19 +05'30'

AMIT KUMAR GUPTA
COMPANY SECRETARY & COMPLIANCE OFFICER
(ACS -15754)

Encl.: a/a.

Press Release

LUPIN

BSE: 500257	NSE: LUPIN	REUTERS: LUPIN.BO	BLOOMBERG: LPCIN

Lupin and Galenicum Sign License and Supply Agreement for Semaglutide in 23 Countries

MUMBAI, BARCELONA, ZUG, Switzerland, January 21, 2026: Global pharma major Lupin Limited today announced a licensing and supply agreement through its subsidiary Lupin Atlantis Holdings SA (LAHSA) with Galenicum Health, S.L.U. (Galenicum) for finished formulations of injectable Semaglutide, a GLP-1 receptor agonist.

As per the agreement, Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally, including Canada, Europe, Southeast Asia and Latin America. Lupin is well-positioned to expand its leadership in diabetes care and obesity beyond India with this Semaglutide partnership.

"Our partnership with Galenicum marks a strategic milestone in strengthening Lupin's Semaglutide portfolio. As diabetes continues to escalate globally and obesity emerges as a major global health priority, Semaglutide stands out as a critical therapy. This collaboration enables us to capitalize on worldwide growth opportunities in the expanding GLP-1 market. With our extensive commercial presence across Canada, Europe, Southeast Asia, and Latin America we are positioned to scale access at the right moment – further reinforcing our commitment to delivering high-quality, cost-effective medicines and expanding access to Semaglutide for patients in these regions," said **Fabrice Egros, President, Corporate Development, Lupin.**

Semaglutide is a generic form of glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar and appetite. It is mainly prescribed for adults with Type 2 Diabetes, alongside diet and exercise, and is also used for long-term weight management in adults with obesity or overweight conditions.

"This partnership is a cornerstone of our strategy to scale high-impact volumes of Semaglutide globally. At Galenicum, we have invested heavily in our GLP-1 development pipeline to meet the surging demand for these life-changing therapies. Our goal is clear: to be a leader in the B2B GLP-1 space, providing our partners with the reliability, scale, competitiveness, and quality required to transform patient care worldwide," said **Joaquim Domingo, co-founder of Galenicum**.

About Lupin

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory,

cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 24,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

About Galenicum

Galenicum is a global pharmaceutical company headquartered in Esplugues de Llobregat, Barcelona, Spain, specializing in the development, manufacturing, and commercialization of generic medicines and value-added generics. With a focus on affordability and quality, Galenicum distributes its products across more than 70 countries worldwide, serving patients and healthcare systems in Europe, Latin America, Asia, and Africa.

The company maintains a diversified portfolio across key therapeutic areas, including cardiovascular, central nervous system, pain management, and anti-infectives. Galenicum has a particularly strong focus and significant developments in the field of diabetics, such as groundbreaking work on GLP-1s.

Galenicum operates a state-of-the-art manufacturing facility and dedicated R&D centers, supported by a committed team. Galenicum is driven by the mission of providing affordable and reliable therapeutic options to improve global patient health.

To know more, visit www.lupin.com or follow us on LinkedIn
https://www.linkedin.com/company/lupin

To know more, visit www.galenicum.com or follow us on LinkedIn
https://www.linkedin.com/company/galenicum-health

For further information or queries, please contact

Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications, Lupin
rajalakshmiazariah@lupin.com

Maria del Mar Fernández San Martín
Chief People & Transformation Officer, Galenicum
Mar.Fernandez@galenicum.com